Gillette/Energizer suit
This article was originally published in The Rose Sheet
Executive Summary
Boston, Mass. federal court Judge Patti Saris denies Schick's motion for summary judgment of non-infringement, according to Dec. 19 memorandum and order. Gillette filed suit against Schick in 2003, claiming company's Quattro four-bladed men's razor infringed its proprietary progressive blade geometry technology for multi-blade razors, used in such products as Mach3 and Venus (1"The Rose Sheet" Aug. 13, 2003, p. 3). Firm sought to prevent Quattro launch but Saris denied Gillette's request for preliminary injunction, concluding patent only applied to three-bladed razors (2"The Rose Sheet" Jan. 19, 2004, In Brief). Her ruling was later overturned by Federal Circuit Court of Appeals. Court document notes Gillette is not seeking summary judgment of infringement; case will likely now proceed to trial...
You may also be interested in...
Razor wars ceasefire called
Gillette and Schick have reached a settlement on "the vast majority of litigation between the companies," Gillette spokesperson says Feb. 17. Procter & Gamble and Energizer divisions have filed a number of separate patent infringement lawsuits against each other over the past few years as both marketers continued to up the ante in razor innovations. Most recently, Schick filed a motion for summary judgment of non-infringement in a case in which Gillette claimed Schick Quattro four-bladed men's razor infringed its proprietary blade technology; however that motion was denied by a Boston, Mass. federal court (1"The Rose Sheet" Jan. 2, 2005, In Brief)...
Gillette Patent Infringement Suit Against Schick Aims To Cut Out Competition
Gillette is seeking to thwart the debut of Schick Quattro men's razor, slated to launch in September, with a patent infringement lawsuit against razor marketer Energizer
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.